Our R01 grant aiming at blocking tumor growth and metastasis in highly aggressive breast cancers has been funded. In this exciting project, we will target highly aggressive breast cancers with our newly developed inhibitor.
Categories: Grant
Our new R01 grant is funded by the NIH/NCI
This 5-year grant will address the mechanisms of resistance to chemotherapy in highly aggressive breast cancers using cutting-edge methodologies, including testing our recently developed LOX inhibitors. NEW positions are available for highly motivated postdocs and Read more…
0 Comments